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radiotherapy in human cancer models in vitro and in mouse 
xenografts.  
 
Conclusion: Conclusion: GRP78 is a molecular target for the 
development of novel radiation sensitizing agents. Anti-
GRP78 antibodies enhance the efficacy of radiotherapy when 
administered IV to mouse models of human cancer. 
 
 
Poster: Radiobiology track: Tumour biology and 
microenvironment  
 
 
PO-0986  
MiR-143 inhibits tumour progression by targeting STAT3 in 
esophageal squamous cell carcinoma 
B. Li
1Shandong Cancer Hospital and Institute, Departments of 
Radiation Oncology Chest Section- Shandong Cancer Hospital 
and Institute, Jinan, China 
1, S.C.H.&.I. Jia liu1, S.C.H.&.I. Yu Mao1 
 
Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-143 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor tissue samples were 
obtained from 40 patients. MiR-143 and STAT3 protein 
expression levels in these clinical samples and three ESCC 
cell lines were determined by quantitative RT–PCR and 
western blot. The relationship between expression level of 
miR-143 and clinical parameters were explored by one-way 
ANOVA. The specific targeting site of miR-143 in the 3’-UTR 
of STAT3 was identified using dual-luciferase reporter assays. 
Then, the effects of ectopic miR-143 or STAT3 expression on 
proliferation, cell cycle distribution, migration and invasion 
were determined in colony-forming assay, flow cytometry 
and transwell assay. The effect of miR-432 on tumor 
progression in vivo was determineded by performing tumor 
formation assay in nude mice. The role miR-143 in regulating 
cell cycle signaling, epithelial-mesenchymal transition and 
MMP up-regulation through repressing STAT3 was explored by 
analyzing the expression level of the downstream proteins. 
 
Results: MiR-143 expression was downregulated in 90% of the 
ESCC clinical samples and its expression level was associated 
with the lymph node metastasis(LNM), invasion and TNM 
stage in ESCC patients. Functional experiments showed that 
ectopic expression of miR-143 could inhibit tumor cell 
proliferation, migration and invasion by supressing STAT3 in 
vitro. Animal experiments showed that the size of 
subcutaneous tumors derived from miR-143 overexpressing 
cells were significantly smaller than that of empty vector 
expressing cells. Further studies verified that miR-143 might 
regulate cell cycle, EMT and MMP up-regulation by targeting 
STAT3 and hence, lead to the suppresion of ESCC cell 
proliferation, migration and invasion. 
 
Conclusion: Our study showed that miR-143 could act as a 
tumor suppressor through the inhibition of proliferation, 
migration and invasion by directly targeting STAT3 and 
subsequently mediates the downstream proteins. Thus, miR-
143 has significant value in clinical and may serve as a 
prognostic marker and therapeutic target in the future. 
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Purpose or Objective: The objective of this study was to 
investigate the biological role of miR-432 in esophageal 
squamous cell carcinoma (ESCC) progression and its 
underlying mechanism. 
 
Material and Methods: Surgical tumor specimens and 
adjacent tissue samples were obtained from 40 patients. 
Pearson correlation coefficients and linear regression model 
were used to explore the bivariate correlations between miR-
432 and IGSF3 expression levels and one-way ANOVA were 
used to estimate the relationship between expression level of 
miR-432 and clinical parameters. Then the effects of ectopic 
miR-432 or IGSF3 expression on proliferation and apoptosis 
were determined using miR-432 over-expression or 
knockdown cells in colony-forming assay and flow cytometry, 
and the effects on cell migration and invasion were 
determined using a transwell assay. On the other hand, 
bioinformatic analysis were performed to assess the 
relationship between IGSF3 and miR-432, and this 
relationship was identified using a dual-luciferase reporter 
assay. Finally, the biological consequences of miR-432-
mediated suppression of IGSF3 expression in ESCC cell lines 
were also determined by performing colony-forming assay, 
flow cytometry and trasnswell assay. 
 
Results: MiR-432 expression was downregulated in 93% 
(37/40) of the ESCC clinical samples and its expression level 
was associated with LNM and TNM stage in ESCC patients. 
Functional experiments showed that over-expression of miR-
432 induced an inhibition of cell proliferation, promotion of 
apoptosis and suppression of cell migraion and invasion in 
vitro by targeting IGSF3. 
 
Conclusion: In conclusion, our results established a 
functional link between miR-432 and IGSF3 expression in 
esophageal cancer, demonstrating that IGSF3 was directly 
repressed by miR-432, which subsequently effects the tumor 
biological process. Collectively, this finding not only helped 
us understand the molecular mechanism of esophageal 
carcinogenesis, but also gave us a strong rationale to further 
investigate miR-432 as a potential biomarker and therapeutic 
target for esophageal cancer. 
 
PO-0988  
Combined treatment strategies for microtubule interfering 
agent-resistant tumors 
A. Broggini-Tenzer
1University Hospital Zürich, Department of Radiation 
Oncology, Zurich, Switzerland 
1, A. Sharma1, S. Bender1, K. Nytko-
Karouzakis1, M. Pruschy1 
 
Purpose or Objective: Tumor cells are the major targets for 
classic anticancer treatment modalities. At the same time 
other cell types within the tumor microenvironment are also 
targeted and co-determine the treatment response. 
Resistances to specific treatment modalities are therefore 
not only linked to the mutated genetic background of the 
tumor cells but also to the interaction of tumor cells with the 
tumor microenvironment. Thus targeting of important 
elements of the microenvironment is a promising strategy to 
overcome treatment resistances in solid tumors. Here we 
mechanistically investigate in different clinically relevant 
microtubule-stabilizing agent (MSA)-refractory tumor models 
the potency of combined treatment modalities of MSAs, 
inhibitors of angiogenesis and ionizing radiation to overcome 
MSA-resistance. 
 
Material and Methods: Rationally designed single and 
combined treatment regimens of ionizing radiation, 
microtubule stabilizing (taxane, epothilone) and de-
stabilizing agents and anti-angiogenics compounds were 
investigated in genetically defined MSA-sensitive and MSA-
resistant lung and colon adenocarcinoma cell lines in vitro 
and in the corresponding tumor xenografts in vivo. 
 
Results: While MSAs potently inhibited A549wt and 
endothelial cell proliferation, no anti-proliferative effect was 
observed in the corresponding mutated MSA-resistant tumor 
cells. Importantly, MSAs did not block anymore pro-survival 
auto- and paracrine signaling from resistant tumor cells by 
downregulation of HIF1-alpha transcriptional activity and 
subsequent secretions of HIF-1alpha-mediated growth factors 
and cytokines like VEGF. Thereby continuous pro-survival 
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signaling from these resistant tumor cells resulted in an 
additional level of treatment resistance towards the 
combined treatment modality of MSAs and ionizing radiation 
in vivo. However, combined treatment of MSAs with clinically 
relevant mTOR-signaling- or VEGF-antagonists strongly re-
sensitized MSA-resistant tumors (lung and colon carcinoma 
models) to the corresponding MSA. Interestingly, a novel 
clinically relevant microtubule-destabilizing agent, which is 
still active in MSA-resistant tumors, successfully overcame 
MSA-resistance in the lung and colon carcinoma models, 
downregulated the HIF1-alpha related aggressive tumor 
phenotype and strongly sensitized for ionizing radiation 
(bolus and metronomic scheduling). 
 
Conclusion: These data demonstrate that the interaction 
between the tumor cell compartment and the tumor 
microenvironment strongly determines the tumor response to 
the combined treatment modality of ionizing radiation and 
microtubule interfering agents. A combined treatment 
modality of microtubule interfering agents with 
antiangiogenic agents is potent to overcome tumor cell-
linked MSA-resistance and should be considered as clinical 
strategy for MSA-refractory tumor entities alone and in 
combination with radiotherapy. 
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Purpose or Objective: We aimed to evaluate the 
pathological hypoxic and perfusion effects of Trastuzumab 
(T) and/or Cisplatin (C) in HER2+ oesophageal 
adenocarcinoma xenograft (OE19) which may potentially 
direct future clinical adjunctive therapy. 
 
Material and Methods: SCID mice (n=17) bearing 
subcutaneous OE19 tumours were treated with either (i) 
Cisplatin 4mg/kg once a week, (ii) Trastuzumab 20mg/kg 
twice a week or (iii) Cisplatin and Trastuzumab for 2 weeks. 
Intraperitoneal Pimonidazole (Pm), an exogenous hypoxic 
marker, and intravenous Hoechst 33342 (Ho), a perfusion 
marker, were injected 2 hours and 1 minute prior to tumour 
excision, respectively. Tumours were immediately snap-
frozen and 10μm frozen sections were obtained for 
immunofluorescence study. Following fixation, non-specific 
binding was blocked using 10% normal goat serum. The 
sections were then incubated overnight at 4°C with primary 
Pimonidazole FITC labelled mouse monoclonal antibody at 
1:25 concentration. Propidium iodide (PI) was used as a 
counterstain to highlight morphology. Tumour sections were 
scanned using different filters for Pm (green), Ho (blue) and 
PI (red) on a fluorescence microscope at x100 magnification 
(Figure 1).  
 
 
 
Image analysis was performed using the ImageJ software. 
Percentage areas stained with Pm (hypoxic fraction/HF) and 
Ho (perfusion fraction/PF) were derived and mean (%) ± SD 
are presented. Difference in the HF and PF between 
Trastuzumab (T) and non-Trastuzumab (NT) treated animals 
were analysed. 
 
Results: Overall, tumour periphery was better perfused in 
most tumours but there was no consistent hypoxic 
intratumoral spatial localisation. There was an inverse spatial 
relationship between Pm and Ho fluorescence in 10/17 
tumours, colocalisation in 3/17 and no relationship found in 4 
tumours. Trastuzumab-treated tumours (HF 38%±17) were 
less hypoxic compared to the NT group (HF 50%±13) and these 
tumours were also better perfused (PF: T 46%±25, NT 
39%±16). Cisplatin-treated tumours had the highest HF 
(50%±13) and lowest PF (39%±16) compared to Trastuzumab 
(HF 34%±13, PF 48%±26) and combination therapy (HF 
41%±21, PF 45%±27). 
 
Conclusion: Trastuzumab appeared to exert the predominant 
proangiogenic effect with improved perfusion and reduced 
intratumoral hypoxia, although these effects were diminished 
with combination therapy. These data suggest that the 
addition of hypoxia-modifying agents might be tested as an 
adjunctive therapy, particularly in those not eligible or fit for 
Trastuzumab therapy. 
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